Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic Keating

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The European Respiratory Journal|November 26, 2021
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!Tom Kotsimbos, David Kaye, Dominic Keating
Respirology Case Reports|July 28, 2025
A Crumpet, a Canine and a Cryoprobe: A Case of Tooth AspirationMatthew Donnan, Melanie Wong, Elina Chi, et al.
The European Respiratory Journal|March 7, 2020
Re-imagining cystic fibrosis care: next generation thinkingCatherine Rang, Dominic Keating, John Wilson, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 28, 2018
Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic FibrosisMichael Pallin, Dominic Keating, David M Kaye, et al.
BMJ Open Respiratory Research|August 20, 2019
CNS imaging studies in cystic fibrosis patients presenting with sudden neurological eventsSamantha Ellis, Catherine Rang, Tom Kotsimbos, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 30, 2016
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECOElena K Schneider, Felisa Reyes-Ortega, John W Wilson, et al.
Respiratory Medicine|March 2, 2022
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and massive hemoptysis: The rationale for bronchial artery embolizationWarren Clements, Georgina Venn, David McGiffin, et al.
Clinical Science (London, England : 1979)|June 15, 2017
Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatmentDeirdre Edgeworth, Dominic Keating, Matthew Ellis, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|February 11, 2021
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extensionSusannah J King, Audrey C Tierney, Deirdre Edgeworth, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 19, 2017
Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota compositionAnton Y Peleg, Jocelyn M Choo, Katherine M Langan, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The European Respiratory Journal|November 26, 2021
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!Tom Kotsimbos, David Kaye, Dominic Keating
Respirology Case Reports|July 28, 2025
A Crumpet, a Canine and a Cryoprobe: A Case of Tooth AspirationMatthew Donnan, Melanie Wong, Elina Chi, et al.
The European Respiratory Journal|March 7, 2020
Re-imagining cystic fibrosis care: next generation thinkingCatherine Rang, Dominic Keating, John Wilson, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 28, 2018
Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic FibrosisMichael Pallin, Dominic Keating, David M Kaye, et al.
BMJ Open Respiratory Research|August 20, 2019
CNS imaging studies in cystic fibrosis patients presenting with sudden neurological eventsSamantha Ellis, Catherine Rang, Tom Kotsimbos, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 30, 2016
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECOElena K Schneider, Felisa Reyes-Ortega, John W Wilson, et al.
Respiratory Medicine|March 2, 2022
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and massive hemoptysis: The rationale for bronchial artery embolizationWarren Clements, Georgina Venn, David McGiffin, et al.
Clinical Science (London, England : 1979)|June 15, 2017
Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatmentDeirdre Edgeworth, Dominic Keating, Matthew Ellis, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|February 11, 2021
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extensionSusannah J King, Audrey C Tierney, Deirdre Edgeworth, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 19, 2017
Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota compositionAnton Y Peleg, Jocelyn M Choo, Katherine M Langan, et al.
Pageof 3